Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales Analysis by Customer, Product & Application Type The global digital therapeutics market will witness a robust CAGR of 31.4%, valued at $3.02 billion in 2021, expected to appreciate and reach $35.78 billion by 2030, confirms Strategic Market Research. The industry provides adequate therapeutic interventions for the patients through some highly advanced software programs as well as devices to treat, prevent, or manage medical conditions such as Type-2 Diabetes, CHF, obesity, Alzheimer's disease, dementia, asthma, substance abuse, ADHD, hypertension, anxiety, depression, mobile health (mHealth) with strategies rooted in cognitive behavioral therapy. The software application can be used independently or combined with devices, medications, or other medicines to provide patient care and improve health outcomes. In USA, the Digital therapeutics market is expected to grow tenfold in the next 3 to 5 years. Over the past few years, investments by digital- therapeutics organizations for patient healthcare in USA have increased by an average of 40% per year, thereby reaching more than USD 1 billion in 2021. Furthermore, In April 2020, The Food and Drug Administration of the U.S. released guidelines and has planned to expand the accessibility of digital therapeutic devices for psychiatric patients. It also aimed to subsidize those people who followed the guidelines and practiced social isolation without a clinic visit during the COVID-19 pandemic situation. The increase in adoption of mobiles & tablets that are coupled with healthcare Apps, Rise of focus on preventive healthcare are the major growth drivers, with North America remaining the dominating market region. Furthermore, in the healthcare sector, digital-therapeutics has augmented the usage of A.I., as well as virtual reality for solving a plethora of problems that exist in the industry. A.I. plays a significant role in digital-therapeutics by increasing the engagement of the software-based treatments. AI-enabled digital-therapeutics provide adeqaute diagnosis & personalized care as well as anticipates the variety of challenges and requirements based on patient’s behavior. For example, the advent of AI in digital-therapeutics has adequately guided healthcare professionals to understand the daily patterns & requirements of the patients, which, in turn, enabled them to provide much better guidance and support. Moreover, with the usage of AI in digital-therapeutics, the early symptoms of some serious diseases like diabetes, dementia, Alzheimer’s disease, etc. can be easily detected. All of the above-mentioned statements are expediting the growth of the market significantly throughout the forecasted time-frame. Market Drivers – Increase in chronic diseases, adoption of mobile phones, and increase in focus on preventive health care The rise in the number of chronic diseases leads to changes in the patients' lifestyles. According to the study published by "The Longitudinal Ageing Study in India (LASI)," in January 2021, approximately 75 million who aged above 60 years suffer from chronic diseases. About 45 million people have cardiovascular disease and hypertension; about 20 million have diabetes. Such conditions are progressive with age, and with the high prevalence of the geriatric population, the overall size of the digital therapeutics market is projected to rise exponentially. An increase in mobile phones and tablets with inbuilt social applications helps patients understand, analyze, and assess their health periodically. As per Kepios, internet users are growing globally at an annual rate of 7.6%, i.e., an average addition of 900,000 new users every day. This helps make specific changes in the lifestyle adopted and usage of medicines. There is a high rate of growth in the usage of technology for Therapeutics, especially in developed markets, as consumers are aware of the advanced products for treating medical conditions. As per the Organization for Economic Co-operation and Development, healthcare spending increased significantly in 2020, as the spending in the healthcare industry has increased in many OECD countries. Preliminary healthcare spending in almost 16 countries across the globe suggested that the per capita health had increased by around 4.9% in 2020. The preference also shifted towards advanced services in the medical field, including the growing demand for innovations in therapeutic devices. Restraints- Data privacy and security issues related to patients Most social healthcare applications don't get approvals from federal initiatives due to product quality, reliability of treatment decisions, data privacy, and security issues. Moreover, a lack of proper healthcare insurance is also plummeting the market's growth. WHO reported that around 50% of the global population is deprived of proper healthcare services. Around 28.0 million people, or 8.6 percent of the population, lacked health insurance worldwide in 2020. Opportunities – Advent of Emerging markets in the developing nations Emerging economies like China, MiddleEast, and India are expected to cater to extensive opportunities in future for digital-therapeutics. The government of these countries are investing an enormous amount of money in R&D activities for improvisation of the digital-therapeutic technologies to great extents. China’s research study revealed that Bluestar Rx is one of the most efficient digital-therapeutics systems for the treatment of individuals suffering from Type 1 & 2 Diabetes. It adequately monitors the pH level of diabetes so that it doesn’t exceed its threshold level of 7.34 by regularly testing the blood sugar levels & controlling it with proper medication & exercise. Furthermore, SMR’s research have revealed that China’s R&D sector for digital-therapeutics accounts for upto 20% of all the expenditure of R&D activities on digital-therapeutics worldwide. Moreover, rise in usage of AI and mobile technologies have improvised the role of digital-therapeutics in the healthcare sector and are hence expected to provide substantial growth opportunities for the market in future. Over the past few years, the process of digital-therapeutics integration with medicines for the improvisation of patient health outcomes have witnessed an exponential growth rate worldwide. This, in turn, has attracted the interest of Big-Pharmas like Thermo Fisher, GE Healthcare, Medtronic, etc, to invest in Digital-Therapeutics through strategic collaborations with the tech-giants worldwide. Global Digital Therapeutics Market Analysis Of Different Segments Based on Sales Channel B2C Patients Caregivers B2B Providers Payers Employers Pharmaceutical Companies Other Buyers Based on Product Type Software Device Based on Application Preventive Applications Prediabetes Obesity Nutrition Lifestyle Management Other Preventive Applications Treatment/Care-related Applications Diabetes CNS Disorders Mental Health Disorder Other CNS Digital therapeutics Chronic Respiratory Disorders Musculoskeletal Disorders Cardiovascular Diseases Smoking Cessation Medication Adherence Gastrointestinal Disorders Substance Use & Addiction Management Rehabilitation & Patient Care Other Treatment/Care-related Applications Based on Region North America US Canada Europe UK Germany France Spain Italy Rest of Europe (RoE) APAC Japan China India Rest of the APAC Rest of the World (RoW) Based on sales channels, the B2B segment dominated the overall market with a steady CAGR in the digital therapeutic device market during the estimated period. It is primarily attributed to the increase in awareness among payers, providers, and employers about the benefits of digital Therapeutics and wellness with the inclination of pharmaceutical companies to integrate digital Therapeutics with drug products. Based on Product Type, the software segment dominated the overall market with a steady CAGR during 2020 due to the increase in adoption of mobile phones and usage of the internet across the developing nations. As per a survey, done by Pew-Research Centre, the adoption rate of smartphones in U.S. was almost 70.5% in 2020, which can further help in the overall usage of healthcare applications. Based on Application, the Treatment/Care-related Applications dominated the overall market with a steady CAGR during 2020. As per the International Diabetes Federation (I.D.F.), in 2021, globally, 536 million adults between the ages of 20 and 79 were suffering from diabetes, which will rise to 783 million by 2045. In most countries, the proportion of people with type 2 diabetes is increasing, and 79% of adults with diabetes live in low-income countries, where 1 in 5 people above the age of 65 years have diabetes. This is due to the increase in obesity, the economic burden of treatment, and the cost & investments in digital-therapeutics market. Based on Region, North America held a significant market share of 40 percent in 2020 and is also expected to propel at a steady CAGR, with U.S. digital therapeutics market being the major one, followed by Europe's digital therapeutics market. In January 2021, as per the C.D.C., 6 in 10 adults in the U.S. are affected by chronic disease. These conditions pose around USD 3.8 trillion of healthcare costs to the country's healthcare system every year. This is attributed to the factors such as the increase in the new start-ups, government initiatives to support technological advancements, and increasing investments in digital Therapeutics that drive market growth in this region. The market value of digital Therapeutics in the European Union is expected to reach USD 4.86 Bn in 2030, and the overall CAGR of Europe's digital therapeutics market was 20.71% during the forecasted period. Report Attribute Details Forecast Period 2021-2030 Market size value in 2021 USD 3.02 Billion Revenue forecast in 2030 USD 35.26 Billion Growth rate 31.4% Base year for estimation 2021 Historical data 2015-2019 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Sales Channel,By Product, By Application, and By Region. By Sales Channel B2C and B2B By Product Software and Devices By Application Preventive Applications and Treatment/Care-related Applications By Region North America,Europe, Asia Pacific And LAMEA Country Scope U.S. , Canada , France, Germany ,U.K. , China , Japan, India , South Korea, Mexico, Brazil ,U.A.E. etc. Company Usability Profiles 2MORROW, Medtronic Plc., Akili Interactive Labs, Inc., Click Therapeutics, Inc., Fitbit, Happify, Inc., Kaia Health, Livongo Health, Omada Health, Pear Therapeutics, Inc., Proteus Digital Health, Inc., Resmed, Voluntis, Inc., Welldoc, Inc., f-star therapeutics, omega therapeutics, g1 therapeutics, gsk digital therapeutics, q digital, viridian therapeutics Global Digital Therapeutics Market Competitive Landscape Analysis The competitive landscape analysis provides information about crucial competitors prevailing in the worldwide market environment. The comparison is performed based on overall revenue generation, market initiatives, company overview, investment in R&D, company financials, company strengths and weaknesses, global presence, production capacity, production sites and facilities, market potential, etc. 2MORROW, Inc. Akili Interactive Labs, Inc. Click Therapeutics, Inc. Fitbit, Inc. (Twine Health, Inc.) Happify, Inc. Kaia Health Livongo Health, Inc. Medtronic Plc. Omada Health, Inc. Pear Therapeutics, Inc. Proteus Digital Health, Inc. Resmed, Inc. (Propeller Health) Voluntis, Inc. Welldoc, Inc. f-star therapeutics omega therapeutics g1 therapeutics gsk digital therapeutics q digital viridian therapeutics Recent Developments In April 2022, Welldoc partnered with Dexcom, which helped in providing BlueStar with a single platform for improved health for people suffering from Type-2 Diabetes. This partnership brought together the two most challenging and independent elements of diabetes management – glucose monitoring and the impact of lifestyle choices through a new app experience. Users will be able to manage multiple facets of their health while also improving data sharing with their care team. In March 2022, Tufts Health Plan and Spectrum Health Systems collaborated with Pear Therapeutics to test F.D.A. with approved digital Therapeutics to assist people with substance use disorders and improvise their recovery journeys. It will be executed by providing solutions for improved treatment access and care innovation journeys to ensure access to the resources and treatments needed to support on a recovery journey from substance use disorder. In February 2021, Philips announced the acquisition of BioTelemetry, Inc., one of the leading US-based providers of remote cardiac diagnostics and monitoring, therapeutic devices, telehealth, and informatics to transform the delivery of health care with integrated solutions. In June 2020, MedRhythms, a Maine-based digital therapeutics company, received Food and Drug Administration clearance because of its patented-digital-therapeutic that uses sensors, music, and software for the treatment of chronic-stroke walking deficits; these impairments are strongly linked to the risk of falling, lack of independence, and decreased quality of life and to address a significant unmet needs in healthcare. On February 2022, DynamiCare Health Inc., a digital therapeutics company, received Breakthrough Device Designation for DCH-001 from the U.S. Food and Drug Administration (F.D.A.) to treat tobacco use disorder complicating pregnancy and childbirth. In May 2021, Eli Lilly signed strategic international agreements with four companies to advance connected solutions and streamline diabetes care management for individuals living with the disease outside of the United States and to offer unique diabetes management platforms that will be compatible with Tempo Smart Button and Lilly's Tempo Pen and to support people with diabetes and healthcare professionals. Frequently Asked Question About This Report What is the forecasted duration of the report? The forecast is from 2020 to 2030. What is the digital therapeutics market size? Digital therapeutics market size in 2021 was $3.02 Bn at a promising CAGR of 31.4%. It will grow exponentially to reach $35.78 Bn by 2030. Which application segment will have the highest market share in the future? Care-related/ Treatment Applications will dominate the overall market. Emerging countries have ample opportunities for the growth and adoption of the market; will this scenario continue in the next five years? Yes,.the emerging countries will have ample opportunities for the growth and adoption of the market; and this entire scenario is expected to continue in the next five years. What is digital Therapeutics D.T.X.? DTX Digital Therapeutics are mainly evidence-based therapeutic interventions that are mostly drove by software to manage, prevent, or treat medical diseases or disorders. What do better Therapeutics do? Creates new treatments to reverse the progression of the disease, inform clinical decisions, and improve quality of life. What are prescription digital therapeutics? Prescription digital therapeutics is a software program that physicians prescribe as a form of treatment that captures patients information about symptoms or progress that their providers can share or access remotely. Sources https://www.evidera.com/digital-therapeutics-past-trends-and-future-prospects/ https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-digital-health-devices-treating-psychiatric-disorders-during-coronavirus-disease https://www.iipsindia.ac.in/sites/default/files/LASI_India_Report_2020_compressed.pdf https://datareportal.com/social-media-users https://www.oecd.org/health/health-expenditure.htm https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases https://www.pewresearch.org/internet/fact-sheet/mobile/ https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html https://www.cdc.gov/chronicdisease/resources/infographic/chronic-diseases.htm https://www.welldoc.com/news/welldoc-dexcom-expand-partnership-to-offer-integrated-type2-diabetes-management/ https://tuftshealthplan.com/visitor/company-news/2021/tufts-health-plan-supports-members-in-recovery-fro https://www.philips.com/aw/about/news/archive/standard/news/press/2021/20210209-philips-completes-the-acquisition-of-biotelemetry-inc.html https://www.prnewswire.com/news-releases/medrhythms-receives-fda-breakthrough-device-designation-for-chronic-stroke-digital-therapeutic-301076597.html https://www.hmpgloballearningnetwork.com/site/ap/news/dynamicare-digital-therapeutic-smoking-cessation-pregnant-women-gets-breakthrough#:~:text=DynamiCare%20Health%2C%20a%20digital%20therapeutics,US%20Food%20and%20Drug%20Administration. https://investor.lilly.com/news-releases/news-release-details/lilly-collaborates-internationally-leading-diabetes-technology 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at Market size By bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size By Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Digital Therapeutics Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Market 4.2.1 Global Market, 2021 – 2030 (USD Million) 4.3 Regional Analysis 4.3.1 By region, 2021 - 2030 (USD Million) 4.4 By Sales Channel Analysis 4.4.1 By Sales Channel, 2021 - 2030 (USD Million) 4.5 By Product Type Analysis 4.5.1 By Product Type, 2021 - 2030 (USD Million) 4.6 Application Analysis 4.6.1 By Application, 2021 - 2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 PEST analysis 4.9.2 Porter’s analysis 4.10Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Digital Therapeutics Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Application Analysis 5.11.1. Trends in Application (2014-2020) 5.11.2. Trends in Application (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Digital Therapeutics Manufacturing Sites, Area Served, Product Sales Channel 6.3. Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Sales Channel Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2020-2030) 7.3. B2C 7.3.1. B2C Market, 2021 - 2030 (USD Million) 8.3.1.1 Patients Market, 2021 - 2030 (USD Million) 8.3.1.2 Caregivers Market, 2021 - 2030 (USD Million) 7.4. B2B 7.4.1. B2B Market, 2021 - 2030 (USD Million) 7.4.1.1 Providers Market, 2021 - 2030 (USD Million) 7.4.1.2 Payers Market, 2021 - 2030 (USD Million) 7.4.1.3 Employers Market, 2021 - 2030 (USD Million) 7.4.1.4 Pharmaceutical Companies Market, 2021 - 2030 (USD Million) 7.4.1.5 Other Buyers Market, 2021 - 2030 (USD Million) 8. Global Market: By Product Type Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2020-2030) 8.3. Software 8.3.1. Software Market, 2021 - 2030 (USD Million) 8.4. Device 8.4.1. Device Market, 2021 - 2030 (USD Million) 9. Global Market: By Application Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2020-2030) 9.3. Preventive Applications 9.3.1. Preventive Applications Market, 2021 - 2030 (USD Million) 9.3.1.1 Obesity Market, 2021 - 2030 (USD Million) 9.3.1.2 Nutrition Market, 2021 - 2030 (USD Million) 9.3.1.3 Lifestyle Management Market, 2021 - 2030 (USD Million) 9.3.1.4 Prediabetes Market, 2021 - 2030 (USD Million) 9.3.1.5 Other Preventive Applications Market, 2021 - 2030 (USD Million) 9.4. Treatment/Care-related Applications 9.4.1. Treatment/Care-related Applications Market, 2021 - 2030 (USD Million) 9.4.1.1 Diabetes Market, 2021 - 2030 (USD Million) 9.4.1.2 CNS Disorders Market, 2021 - 2030 (USD Million) 9.4.1.2.1 Mental Health Disorder Market, 2021 - 2030 (USD Million) 9.4.1.2.2 Other CNS Digital therapeutics Market, 2021 - 2030 (USD Million) 9.4.2. Chronic Respiratory Disorders Market, 2021 - 2030 (USD Million) 9.4.3. Musculoskeletal Disorders Market, 2021 - 2030 (USD Million) 9.4.4. Cardiovascular Diseases Market, 2021 - 2030 (USD Million) 9.4.5. Smoking Cessation Market, 2021 - 2030 (USD Million) 9.4.6. Medication Adherence Market, 2021 - 2030 (USD Million) 9.4.7. Gastrointestinal Disorders Market, 2021 - 2030 (USD Million) 9.4.8. Substance Use & Addiction Management Market, 2021 - 2030 (USD Million) 9.4.9. Rehabilitation & Patient Care Market, 2021 - 2030 (USD Million) 9.4.10. Other Treatment/Care-related Applications Market, 2021 - 2030 (USD Million) 10. Global Market: Regional Outlook 10.1 North America 10.1.1. North America, By Sales Channel, 2021 - 2030 (USD Million) 10.1.2. North America, By Product Type, 2021 - 2030 (USD Million) 10.1.3. North America, By Application, 2021 - 2030 (USD Million) 10.1.4. North America, By Country, 2021 - 2030 (USD Million) 10.1.4.1. U.S. 10.1.4.1.1. U.S., By Sales Channel, 2021 - 2030 (USD Million) 10.1.4.1.2. U.S., By Product Type, 2021 - 2030 (USD Million) 10.1.4.1.3. U.S., By Application, 2021 - 2030 (USD Million) 10.1.4.2.Canada 10.1.4.2.1. Canada, By Sales Channel, 2021 - 2030 (USD Million) 10.1.4.2.2. Canada, By Product Type, 2021 - 2030 (USD Million) 10.1.4.2.3. Canada, By Application, 2021 - 2030 (USD Million) 10.2. Europe 10.2.1. Europe , By Sales Channel, 2021 - 2030 (USD Million) 10.2.2. Europe Market, By Product Type, 2021 - 2030 (USD Million) 10.2.3. Europe Market, By Application, 2021 - 2030 (USD Million) 10.2.4. Europe Market, By country, 2021 - 2030 (USD Million) 10.2.4.1 U.K. 10.2.4.1.1. U.K. , By Sales Channel, 2021 - 2030 (USD Million) 10.2.4.1.2. U.K. , By Product Type, 2021 - 2030 (USD Million) 10.2.4.1.3. U.K. , By Application, 2021 - 2030 (USD Million) 10.2.4.2. Germany 10.2.4.2.1. Germany, By Sales Channel, 2021 - 2030 (USD Million) 10.2.4.2.2. Germany , By Product Type, 2021 - 2030 (USD Million) 10.2.4.2.3. Germany , By Application, 2021 - 2030 (USD Million) 10.2.4.3. France 10.2.4.3.1. France , By Sales Channel, 2021 - 2030 (USD Million) 10.2.4.3.2. France , By Product Type, 2021 - 2030 (USD Million) 10.2.4.3.3. France , By Application, 2021 - 2030 (USD Million) 10.2.4.4. Rest of Europe 10.2.4.4.1. Rest of Europe, By Sales Channel, 2021 - 2030 (USD Million) 10.2.4.4.2. Rest of Europe, By Product Type, 2021 - 2030 (USD Million) 10.2.4.4.3. Rest of Europe, By Application, 2021 - 2030 (USD Million) 10.3. Asia Pacific 10.3.1. Asia Pacific By Sales Channel, 2021 - 2030 (USD Million) 10.3.2. Asia Pacific , By Product Type, 2021 - 2030 (USD Million) 10.3.3. Asia Pacific , By Application, 2021 - 2030 (USD Million) 10.3.4. Asia Pacific By country, 2021 - 2030 (USD Million) 10.3.4.1. China 10.3.4.1.1. China By Sales Channel, 2021 - 2030 (USD Million) 10.3.4.1.2. China By Product Type, 2021 - 2030 (USD Million) 10.3.4.1.3. China By Application, 2021 - 2030 (USD Million) 10.3.4.2. India 10.3.4.2.1. India By Sales Channel, 2021 - 2030 (USD Million) 10.3.4.2.2. India By Product Type, 2021 - 2030 (USD Million) 10.3.4.2.3. India By Application, 2021 - 2030 (USD Million) 10.3.4.3. Japan 10.3.4.3.1. Japan By Sales Channel, 2021 - 2030 (USD Million) 10.3.4.3.2. Japan By Product Type, 2021 - 2030 (USD Million) 10.3.4.3.3. Japan By Application, 2021 - 2030 (USD Million) 10.3.4.4. South Korea 10.3.4.4.1. South Korea By Sales Channel, 2021 - 2030 (USD Million) 10.3.4.4.2. South Korea By Product Type, 2021 - 2030 (USD Million) 10.3.4.4.3. South Korea By Application, 2021 - 2030 (USD Million) 10.3.4.5. Rest of ASIA PACIFIC 10.3.4.5.1. Rest of ASIA PACIFIC By Sales Channel, 2021 - 2030 (USD Million) 10.3.4.5.2. Rest of ASIA PACIFIC By Product Type, 2021 - 2030 (USD Million) 10.3.4.5.3. Rest of ASIA PACIFIC By Application, 2021 - 2030 (USD Million) 10.4. Latin America 10.4.1. Latin America By Sales Channel, 2021 - 2030 (USD Million) 10.4.2. Latin America By Product Type, 2021 - 2030 (USD Million) 10.4.3. Latin America By Application, 2021 - 2030 (USD Million) 10.4.4. Latin America By country, 2021 - 2030 (USD Million) 10.4.4.1. Brazil 10.4.4.1.1. Brazil By Sales Channel, 2021 - 2030 (USD Million) 10.4.4.1.2. Brazil By Product Type, 2021 - 2030 (USD Million) 10.4.4.1.3. Brazil By Application, 2021 - 2030 (USD Million) 10.4.4.2. Mexico 10.4.4.2.1. Mexico By Sales Channel, 2021 - 2030 (USD Million) 10.4.4.2.2. Mexico By Product Type, 2021 - 2030 (USD Million) 10.4.4.2.3. Mexico By Application, 2021 - 2030 (USD Million) 10.4.4.3. Rest of Latin America 10.4.4.3.1. Rest of the Latin America, By Sales Channel, 2021 - 2030 (USD Million) 10.4.4.3.2. Rest of the Latin America, By Product Type, 2021 - 2030 (USD Million) 10.4.4.3.3. Rest of the Latin America, By Application, 2021 - 2030 (USD Million) 10.5. MEA 10.5.1. MEA By Sales Channel, 2021 - 2030 (USD Million) 10.5.2. MEA By Product Type, 2021 - 2030 (USD Million) 10.5.3. MEA By Application, 2021 - 2030 (USD Million) 10.5.4. MEA By Region, 2021 - 2030 (USD Million) 11. Competitive Landscape 11.1 2MORROW, Inc. 11.1.1. Company overview 11.1.2. Financial performance 11.1.3. ProductPortfolio Analysis 11.1.4. Business Strategy & Recent Development 11.2. AKILI INTERACTIVE LABS, INC. 11.2.1. Company overview 11.2.2. Financial performance 11.2.3. Product Portfolio Analysis 11.2.4. Business Strategy & Recent Development 11.3. CLICK THERAPEUTICS, INC. 11.3.1. Company overview 11.3.2. Financial performance 11.3.3. Product Portfolio Analysis 11.3.4. Business Strategy & Recent Development 11.4. FITBIT, INC. (TWINE HEALTH, INC.) 11.4.1. Company overview 11.4.2. Financial performance 11.4.3. Product Portfolio Analysis 11.4.4. Business Strategy & Recent Development 11.5. HAPPIFY, INC. 11.5.1. Company overview 11.5.2. Financial performance 11.5.3. Product Portfolio Analysis 11.5.4. Business Strategy & Recent Development 11.6. Kaia Health 11.6.1. Company overview 11.6.2. Financial performance 11.6.3. Product Portfolio Analysis 11.6.4. Business Strategy & Recent Development 11.7. Livongo Health, Inc. 11.7.1. Company overview 11.7.2. Financial performance 11.7.3. Product Portfolio Analysis 11.7.4. Business Strategy & Recent Development 11.8. Medtronic Plc. 11.8.1. Company overview 11.8.2. Financial performance 11.8.3. Product Portfolio Analysis 11.8.4. Business Strategy & Recent Development 11.9. Omada Health, Inc. 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 11.10. Pear Therapeutics, Inc. 11.10.1. Company overview 11.10.2. Financial performance 11.10.3. Product Portfolio Analysis 11.10.4. Business Strategy & Recent Development 11.11. Proteus Digital Health, Inc. 11.11.1. Company overview 11.11.2. Financial performance 11.11.3. Product Portfolio Analysis 11.11.4. Business Strategy & Recent Development 11.12. Resmed, Inc. (Propeller Health). 11.12.1. Company overview 11.12.2. Financial performance 11.12.3. Product Portfolio Analysis 11.12.4. Business Strategy & Recent Development 11.13. Voluntis, Inc. 11.13.1. Company overview 11.13.2. Financial performance 11.13.3. Product Portfolio Analysis 11.13.4. Business Strategy & Recent Development 11.14. Welldoc, Inc. 11.14.1. Company overview 11.14.2. Financial performance 11.14.3. Product Portfolio Analysis 11.14.4. Business Strategy & Recent Development 11.15. F-star therapeutics 11.15.1. Company overview 11.15.2. Financial performance 11.15.3. Product Portfolio Analysis 11.15.4. Business Strategy & Recent Development 11.16. Omega therapeutics 11.16.1. Company overview 11.16.2. Financial performance 11.16.3. Product Portfolio Analysis 11.16.4. Business Strategy & Recent Development 11.17. G1 therapeutics 11.17.1. Company overview 11.18.2. Financial performance 11.17.3. Product Portfolio Analysis 11.17.4. Business Strategy & Recent Development 11.18. Gsk digital therapeutics 11.18.1. Company overview 11.18.2. Financial performance 11.18.3. Product Portfolio Analysis 11.18.4. Business Strategy & Recent Development 11.19. Q digital 11.19.1. Company overview 11.19.2. Financial performance 11.19.3. Product Portfolio Analysis 11.19.4. Business Strategy & Recent Development 11.20. Viridian therapeutics 11.20.1. Company overview 11.20.2. Financial performance 11.20.3. Product Portfolio Analysis 11.20.4. Business Strategy & Recent Development List of Tables (91 Tables) TABLE 1. Digital Therapeutics MARKET, By Sales Channel, 2020-2030 (USD Million) TABLE 2. Digital Therapeutics MARKET FOR B2C, BY REGION, 2020-2030 (USD Million) TABLE 3. Digital Therapeutics MARKET FOR Patients, BY REGION, 2020-2030 (USD Million) TABLE 4. Digital Therapeutics MARKET FOR Caregivers, BY REGION, 2020-2030 (USD Million) TABLE 5. Digital Therapeutics MARKET FOR B2B, BY REGION, 2020-2030 (USD Million) TABLE 6. Digital Therapeutics MARKET FOR Providers, BY REGION, 2020-2030 (USD Million) TABLE 7. Digital Therapeutics MARKET FOR Payers, BY REGION, 2020-2030 (USD Million) TABLE 8. Digital Therapeutics MARKET FOR Employers, BY REGION, 2020-2030 (USD Million) TABLE 9. Digital Therapeutics MARKET FOR Pharmaceutical Companies, BY REGION, 2020-2030 (USD Million) TABLE 10. Digital Therapeutics MARKET FOR Other Buyers, BY REGION, 2020-2030 (USD Million) TABLE 11. Digital Therapeutics MARKET, By Product Type, 2020-2030 (USD Million) TABLE 12. Digital Therapeutics MARKET FOR Software, BY REGION, 2020-2030 (USD Million) TABLE 13. Digital Therapeutics MARKET FOR Device, BY REGION, 2020-2030 (USD Million) TABLE 14. Digital Therapeutics MARKET, BY APPLICATION, 2020-2030 (USD Million) TABLE 15. Digital Therapeutics MARKET FOR Preventive Applications, BY REGION, 2020-2030 (USD Million) TABLE 16. Digital Therapeutics MARKET FOR Prediabetes, BY REGION, 2020-2030 (USD Million) TABLE 17. Digital Therapeutics MARKET FOR Obesity, BY REGION, 2020-2030 (USD Million) TABLE 18. Digital Therapeutics MARKET FOR Nutrition, BY REGION, 2020-2030 (USD Million) TABLE 19. Digital Therapeutics MARKET FOR Lifestyle Management, BY REGION, 2020-2030 (USD Million) TABLE 20. Digital Therapeutics MARKET FOR Other Preventive Applications, BY REGION, 2020-2030 (USD Million) TABLE 21. Digital Therapeutics MARKET FOR Treatment/Care-related Applications, BY REGION, 2020-2030 (USD Million) TABLE 22. Digital Therapeutics MARKET FOR Diabetes, BY REGION, 2020-2030 (USD Million) TABLE 23. Digital Therapeutics MARKET FOR CNS Disorders, BY REGION, 2020-2030 (USD Million) TABLE 24. Digital Therapeutics MARKET FOR Mental Health Disorder, BY REGION, 2020-2030 (USD Million) TABLE 25. Digital Therapeutics MARKET FOR Other CNS Digital therapeutics, BY REGION, 2020-2030 (USD Million) TABLE 26. Digital Therapeutics MARKET FOR Chronic Respiratory Disorders, BY REGION, 2020-2030 (USD Million) TABLE 27. Digital Therapeutics MARKET FOR Musculoskeletal Disorders, BY REGION, 2020-2030 (USD Million) TABLE 28. Digital Therapeutics MARKET FOR Cardiovascular Diseases, BY REGION, 2020-2030 (USD Million) TABLE 29. Digital Therapeutics MARKET FOR Smoking Cessation, BY REGION, 2020-2030 (USD Million) TABLE 30. Digital Therapeutics MARKET FOR Medication Adherence, BY REGION, 2020-2030 (USD Million) TABLE 31. Digital Therapeutics MARKET FOR Gastrointestinal Disorders, BY REGION, 2020-2030 (USD Million) TABLE 32. Digital Therapeutics MARKET FOR Substance Use & Addiction Management, BY REGION, 2020-2030 (USD Million) TABLE 33. Digital Therapeutics MARKET FOR Rehabilitation & Patient Care, BY REGION, 2020-2030 (USD Million) TABLE 34. Digital Therapeutics MARKET FOR Other Treatment/Care-related Applications, BY REGION, 2020-2030 (USD Million) TABLE 35. Digital Therapeutics MARKET, BY REGION, 2020-2030 (USD Million) TABLE 36. NORTH AMERICA Digital Therapeutics MARKET, BY COUNTRY, 2020-2030 (USD Million) TABLE 37. NORTH AMERICA Digital Therapeutics MARKET, By Sales Channel, 2020-2030 (USD Million) TABLE 38. NORTH AMERICA Digital Therapeutics MARKET, By Product Type, 2020-2030 (USD Million) TABLE 39. NORTH AMERICA Digital Therapeutics MARKET, BY APPLICATION, 2020-2030 (USD Million) TABLE 40. EUROPE Digital Therapeutics MARKET, BY COUNTRY, 2020-2030 (USD Million) TABLE 41. EUROPE Digital Therapeutics MARKET, By Sales Channel, 2020-2030 (USD Million) TABLE 42. EUROPE Digital Therapeutics MARKET, By Product Type, 2020-2030 (USD Million) TABLE 43. EUROPE Digital Therapeutics MARKET, BY APPLICATION, 2020-2030 (USD Million) TABLE 44. ASIA-PACIFIC Digital Therapeutics MARKET, BY COUNTRY, 2020-2030 (USD Million) TABLE 45. ASIA-PACIFIC Digital Therapeutics MARKET, By Sales Channel, 2020-2030 (USD Million) TABLE 46. ASIA-PACIFIC Digital Therapeutics MARKET, By Product Type, 2020-2030 (USD Million) TABLE 47. ASIA-PACIFIC Digital Therapeutics MARKET, BY APPLICATION, 2020-2030 (USD Million) TABLE 48. LAMEA Digital Therapeutics MARKET, BY COUNTRY, 2020-2030 (USD Million) TABLE 49. LAMEA Digital Therapeutics MARKET, By Sales Channel, 2020-2030 (USD Million) TABLE 50. LAMEA Digital Therapeutics MARKET, By Product Type, 2020-2030 (USD Million) TABLE 51. LAMEA Digital Therapeutics MARKET, BY APPLICATION, 2020-2030 (USD Million) TABLE 52. 2MORROW, Inc.: COMPANY SNAPSHOT TABLE 53. 2MORROW, Inc.: OPERATING SEGMENTS TABLE 54. AKILI INTERACTIVE LABS, INC.: COMPANY SNAPSHOT TABLE 55. AKILI INTERACTIVE LABS, INC.: OPERATING SEGMENTS TABLE 56. CLICK THERAPEUTICS, INC.: COMPANY SNAPSHOT TABLE 57. CLICK THERAPEUTICS, INC.: OPERATING SEGMENTS TABLE 58. FITBIT, INC. (TWINE HEALTH, INC.) : COMPANY SNAPSHOT TABLE 59. FITBIT, INC. (TWINE HEALTH, INC.) : OPERATING SEGMENTS TABLE 60. HAPPIFY, INC.: COMPANY SNAPSHOT TABLE 61. HAPPIFY, INC.: OPERATING SEGMENTS TABLE 62. Kaia Health : COMPANY SNAPSHOT TABLE 63. Kaia Health : OPERATING SEGMENTS TABLE 64. Livongo Health, Inc.: COMPANY SNAPSHOT TABLE 65. Livongo Health, Inc.: OPERATING SEGMENTS TABLE 66. Medtronic Plc.: COMPANY SNAPSHOT TABLE 67. Medtronic Plc.: OPERATING SEGMENTS TABLE 68. Omada Health, Inc.: COMPANY SNAPSHOT TABLE 69. Omada Health, Inc.: OPERATING SEGMENTS TABLE 70. Pear Therapeutics, Inc.: COMPANY SNAPSHOT TABLE 71. Pear Therapeutics, Inc.: OPERATING SEGMENTS TABLE 72. Proteus Digital Health, Inc.: COMPANY SNAPSHOT TABLE 73. Proteus Digital Health, Inc.: OPERATING SEGMENTS TABLE 74. Resmed, Inc. (Propeller Health): COMPANY SNAPSHOT TABLE 75. Resmed, Inc. (Propeller Health): OPERATING SEGMENTS TABLE 76. Voluntis, Inc.: COMPANY SNAPSHOT TABLE 77. Voluntis, Inc.: OPERATING SEGMENTS TABLE 78. Welldoc, Inc.: COMPANY SNAPSHOT TABLE 79. Welldoc, Inc.: OPERATING SEGMENTS TABLE 80. F-star therapeutics: COMPANY SNAPSHOT TABLE 81. F-star therapeutics: OPERATING SEGMENTS TABLE 82. Omega therapeutics: COMPANY SNAPSHOT TABLE 83. Omega therapeutics: OPERATING SEGMENTS TABLE 84. G1 therapeutics: COMPANY SNAPSHOT TABLE 85. G1 therapeutics: OPERATING SEGMENTS TABLE 86. Gsk digital therapeutics: COMPANY SNAPSHOT TABLE 87. Gsk digital therapeutics: OPERATING SEGMENTS TABLE 88. Q digital: COMPANY SNAPSHOT TABLE 89. Q digital: OPERATING SEGMENTS TABLE 90. Viridian therapeutics: COMPANY SNAPSHOT TABLE 91. Viridian therapeutics: OPERATING SEGMENTS List of Figures (22 Figures) Figure 1 Digital Therapeutics Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Digital Therapeutics Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Digital Therapeutics Market: Product-Based Estimation Figure 6 Top 20 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Digital Therapeutics, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Digital Therapeutics, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 By Product Type, 2019 vs. 2025 (USD Million) Figure 12 Share, By Application, 2019 vs. 2025 (USD Million) Figure 13 Share, By Sales Channel, 2019 vs. 2025 (USD Million) Figure 14 Geographical Snapshot of the Figure 15 B2B to Witness Higher CAGR in for Sales Channel Segment during Forecast Period. Figure 16 Treatment/Care-related Applications to Witness Higher CAGR in for Application Segment during Forecast Period. Figure 17 Software to Witness Higher CAGR in for Product Type Segment during Forecast Period. Figure 18 North America region Accounted for the Largest Share of the , By Regional Basis, in 2019 Figure 19 Drivers, Restraints, Opportunities, and Challenges Figure 20 North America: Snapshot Figure 21 Asia Pacific: Snapshot Figure 22 Vendor Dive: Evaluation Overview